Global Recombinant Therapeutic Protein Market Size, Share and Trends Analysis Report, By Type (Monoclonal Antibodies, Erythropoietin, Insulin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone, Blood Clotting Factors, Granulocyte-colony stimulating factor, Colony Stimulating Factor, and Others) and By Application (Cancer, Infectious Diseases, Haemophilia, Anaemia, Multiple Sclerosis, and Hepatitis B/C), Forecast (2022-2028)

The recombinant therapeutic protein market is anticipated to grow at a significant CAGR of 6.4% during the forecast period (2022-2028). Therapeutic proteins are laboratory-engineered proteins with medicinal use. Insulin was the first therapeutic protein, developed in 1920 to treat diabetes. Recombinant DNA technology makes it simple to generate proteins in certain host cells such as bacteria, yeast, or mammalian cells under specific circumstances. Recombinant Therapeutic protein is a modified form of a protein that is made using various ways in order to create huge amounts of proteins, change gene sequences, and finally make commercial goods. The complete process of creating a recombinant protein is referred to as recombinant technology. The major factor driving the growth of the global recombinant therapeutic protein market includes the growth in antibody-based therapeutics that has led to research on designing protein scaffolds as a result of recent advances in recombinant proteins. According to the National Center for Biotechnology Information (NCBI), recent advances in protein engineering technologies have enabled drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety and efficacy.

The global recombinant therapeutic protein market is segmented based on type and application. Based on type, the market is sub-segmented into monoclonal antibodies, erythropoietin, insulin, interferon, human growth hormone, follicle-stimulating hormone, blood clotting factors, granulocyte-colony stimulating factor, colony-stimulating factor, and others. Among these types, the monoclonal antibodies segment is expected to propel the growth of the market as they support the immune response and can even induce the accumulation of therapeutic agents at a tumor site by conjugation or fusion. Based on the application, the market is sub-segmented into cancer, infectious diseases, haemophilia, anaemia, multiple sclerosis, and hepatitis b/c.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028
  • Segment Covered-
    • By Type
    • By Application
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape- Abbott Laboratories Ltd., AstraZeneca PLC, Baxter International, F. Hoffmann-La Roche Inc., Johnson & Johnson Services Ltd., Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?
    • Deviation from the pre-COVID-19 forecast
    • Most affected region and segment
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Recombinant Therapeutic Protein Market Report by Segment

By Type

  • Monoclonal Antibodies
  • Erythropoietin
  • Insulin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone
  • Blood Clotting Factors
  • Granulocyte-colony stimulating factor
  • Colony Stimulating Factor
  • Others

By Application

  • Cancer
  • Infectious Diseases
  • Haemophilia
  • Anaemia
  • Multiple Sclerosis
  • Hepatitis B/C

Global Recombinant Therapeutic Protein Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

The report will be delivered within 48-72 hours after payment confirmation